Nasus Pharma (NSRX) Accounts Payables (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Accounts Payables came in at $829000.0 in Q4 2025, up 27.34% YoY from $651000.0 in Q4 2024, and up 24.85% on a QoQ basis from $664000.0 in Q2 2025.
Nasus Pharma (NSRX) Accounts Payables (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Accounts Payables data on file, last reported at $829000.0 in Q4 2025.
- Quarterly Accounts Payables rose 27.34% year-over-year to $829000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $829000.0 (up 27.34% YoY) and the FY2025 annual result came in at $829000.0, up 27.34% from the prior year.
- Accounts Payables climbed to $829000.0 in Q4 2025, from $664000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $829000.0 in Q4 2025 to a low of $651000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Nasus Pharma | 32.04 Mn | 32.04 Mn | - | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 829,000.00 |
| Jun 30, 2025 | 664,000.00 |
| Dec 31, 2024 | 651,000.00 |